These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 25381973

  • 1. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M, Favalli EG.
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [Abstract] [Full Text] [Related]

  • 2. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 3. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K, Hartley L, Solanki K, White D.
    N Z Med J; 2015 May 29; 128(1415):34-40. PubMed ID: 26117510
    [Abstract] [Full Text] [Related]

  • 4. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan 29; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 5. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, González-Mari MV, Laffón A, García-Vicuña R.
    Am J Med; 2005 May 29; 118(5):552-6. PubMed ID: 15866260
    [No Abstract] [Full Text] [Related]

  • 6. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 29; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 7. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 29; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 8. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G, Strehblow C, Fasching P.
    Wien Med Wochenschr; 2010 May 29; 160(9-10):220-4. PubMed ID: 20632149
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.
    Arthritis Res Ther; 2010 May 29; 12(3):R117. PubMed ID: 20553600
    [Abstract] [Full Text] [Related]

  • 10. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May 29; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

  • 11. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug 29; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 12. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.
    Am J Gastroenterol; 2013 Jan 29; 108(1):99-105. PubMed ID: 23032984
    [Abstract] [Full Text] [Related]

  • 13. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug 29; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 14. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I, Valor L, Nieto JC, Montoro M, Carreño L.
    Reumatol Clin; 2014 Aug 29; 10(2):101-4. PubMed ID: 24280444
    [Abstract] [Full Text] [Related]

  • 15. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.
    Ann Rheum Dis; 2007 Oct 29; 66(10):1393-7. PubMed ID: 17613555
    [Abstract] [Full Text] [Related]

  • 16. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.
    Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L.
    Scand J Rheumatol; 2012 Oct 29; 41(6):490-1. PubMed ID: 22985209
    [No Abstract] [Full Text] [Related]

  • 17. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr 29; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 18. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
    Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group.
    Ann Rheum Dis; 2015 Jun 29; 74(6):970-8. PubMed ID: 25710471
    [Abstract] [Full Text] [Related]

  • 19. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
    Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C.
    Rheumatology (Oxford); 2013 Oct 29; 52(10):1914-9. PubMed ID: 23878312
    [Abstract] [Full Text] [Related]

  • 20. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov 29; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.